Gladstone-UCSF Institute of Genomic Immunology Seminar
Tuesday, November 18, 2025

Katy Rezvani, MD, PhD

Vice President and Head of the Institute for Cell Therapy Innovation and Discovery, Department of Institute for Cell Therapy Innovation and Discovery, and Division of Cancer Medicine; Principal Investigator at The University of Texas MD Anderson Cancer Center

Katy Rezvani, MD, PhD, is professor of medicine, director of translational research, medical director of the MD Anderson GMP and Cell Therapy Laboratory and chief, section of cellular therapy, department of stem cell transplant and cellular therapy at MD Anderson Cancer Center. Rezvani joined the faculty at the MDACC in 2012 from the Hammersmith Hospital in London, where she was director of the allogeneic adult stem cell transplant program, medical director of the GMP facility, and director of the Transplant Immunology Research Laboratory. 

Rezvani has an active research laboratory program in transplantation immunology, where the focus of her research group is to study the role of natural-killer (NK) cells in mediating immunity against leukemia and lymphoma as well as glioblastoma and an array of other solid tumors and seeks to understand the mechanisms of tumor-induced NK cell dysfunction. The goal of her research is to develop strategies for genetically engineering NK cells to enhance their in-vivo anti-tumor activity and persistence. She leads the NK immunotherapy program at MD Anderson and translates multiple innovative strategies from bench to bedside, including a first-in-human trial of CAR NK cells in patients with lymphoid malignancies.

Details

Dates
November 18, 2025
Time
10:00-11:00am PST
Location
Mahley Auditorium & Online
Audience
Gladstone and UCSF
Contact(s)







The Gladstone-UCSF Institute of Genomic Immunology Seminar Series showcases speakers at the intersection of genomic technology and immunology research with an aim to engineer the human immune system for therapeutic benefit. Speakers span technology development, synthetic biology, bioengineering, and the development and clinical application of immunotherapy. These talks are open to the Gladstone and UCSF communities.

Optimizing NK Cell Engineering for Therapeutic Efficacy

Diversity, Equity, and Inclusion

At Gladstone, we are committed to providing events and professional development activities that resonate with our community’s diverse members. Our goal is to develop creative programming that encompasses a wide variety of ideas and perspectives to inspire, educate, and engage with everyone within our walls.

We want to effect positive change through our events and activities by providing a platform for discussions on important topics related to increasing diversity and inclusiveness in the sciences.